ATRA Stock Overview
Engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Atara Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.70 |
| 52 Week High | US$2.54 |
| 52 Week Low | US$0.20 |
| Beta | 0.70 |
| 1 Month Change | 0.34% |
| 3 Month Change | -11.09% |
| 1 Year Change | -63.55% |
| 3 Year Change | -94.86% |
| 5 Year Change | -97.00% |
| Change since IPO | -94.17% |
Recent News & Updates
New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
May 14
Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive
May 11Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
May 14Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive
May 11Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
Feb 06Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely
Oct 17Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive
May 18Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Feb 13Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%
Nov 22EMA panel backs approval of Atara's Ebvallo for transplant complication
Oct 14Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre
Sep 28Atara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipeline
Aug 17Atara adds 16% ahead of Phase 2 data for multiple sclerosis candidate
Jul 12Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Intrinsic Value Is Potentially 42% Above Its Share Price
Jul 03Time To Worry? Analysts Just Downgraded Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Outlook
May 11Shareholder Returns
| ATRA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.3% | 0.7% | 1.2% |
| 1Y | -63.6% | 5.0% | 27.7% |
Return vs Industry: ATRA underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: ATRA underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| ATRA volatility | |
|---|---|
| ATRA Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ATRA has not had significant price volatility in the past 3 months.
Volatility Over Time: ATRA's weekly volatility has decreased from 21% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 173 | Pascal Touchon | www.atarabio.com |
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis.
Atara Biotherapeutics, Inc. Fundamentals Summary
| ATRA fundamental statistics | |
|---|---|
| Market cap | US$83.48m |
| Earnings (TTM) | -US$233.11m |
| Revenue (TTM) | US$34.70m |
2.4x
P/S Ratio-0.4x
P/E RatioIs ATRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATRA income statement (TTM) | |
|---|---|
| Revenue | US$34.70m |
| Cost of Revenue | US$209.78m |
| Gross Profit | -US$175.07m |
| Other Expenses | US$58.03m |
| Earnings | -US$233.11m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.94 |
| Gross Margin | -504.48% |
| Net Profit Margin | -671.70% |
| Debt/Equity Ratio | 0% |
How did ATRA perform over the long term?
See historical performance and comparison